CL2020001600A1 - Un conjugado de un análogo de tubulisina con enlazadores ramificados. - Google Patents
Un conjugado de un análogo de tubulisina con enlazadores ramificados.Info
- Publication number
- CL2020001600A1 CL2020001600A1 CL2020001600A CL2020001600A CL2020001600A1 CL 2020001600 A1 CL2020001600 A1 CL 2020001600A1 CL 2020001600 A CL2020001600 A CL 2020001600A CL 2020001600 A CL2020001600 A CL 2020001600A CL 2020001600 A1 CL2020001600 A1 CL 2020001600A1
- Authority
- CL
- Chile
- Prior art keywords
- conjugate
- tubulysin analog
- branched
- branched linkers
- tubulysin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Abstract
La presente invención hace referencia a la conjugación de un compuesto análogo de tubulisina con una molécula de unión a células con enlazadores de cadena ramificada/lateral para tener mejor administración del compuesto conjugado y el tratamiento dirigido de células anómalas. También hace referencia a un método de enlace ramificado de conjugación de una molécula de análogo de tubulisina a un ligando de unión a células, así como a métodos para usar el conjugado en el tratamiento dirigido de cáncer, infecciones y enfermedades autoinmunitarias.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/120454 WO2019127607A1 (en) | 2017-12-31 | 2017-12-31 | A conjugate of a tubulysin analog with branched linkers |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020001600A1 true CL2020001600A1 (es) | 2021-03-19 |
Family
ID=67064953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001600A CL2020001600A1 (es) | 2017-12-31 | 2020-06-15 | Un conjugado de un análogo de tubulisina con enlazadores ramificados. |
Country Status (17)
Country | Link |
---|---|
US (4) | US20200276261A1 (es) |
EP (1) | EP3621652A4 (es) |
JP (2) | JP7262817B2 (es) |
KR (2) | KR102603344B1 (es) |
CN (1) | CN111093707A (es) |
AU (2) | AU2017445144A1 (es) |
BR (1) | BR112020010405A2 (es) |
CA (1) | CA3085634C (es) |
CL (1) | CL2020001600A1 (es) |
EA (1) | EA202091217A1 (es) |
IL (1) | IL275274A (es) |
MX (1) | MX2020006192A (es) |
NZ (1) | NZ764814A (es) |
PH (1) | PH12020550657A1 (es) |
SG (1) | SG11202004801WA (es) |
WO (1) | WO2019127607A1 (es) |
ZA (1) | ZA202003211B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
HUE048574T2 (hu) | 2012-07-12 | 2020-08-28 | Hangzhou Dac Biotech Co Ltd | Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
EP3986476A4 (en) * | 2019-06-24 | 2023-11-15 | Hangzhou Dac Biotech Co., Ltd. | FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL BINDING MOLECULE |
US20230115871A1 (en) * | 2019-06-24 | 2023-04-13 | Hangzhou Dac Biotech Co., Ltd | A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers |
KR20220029725A (ko) * | 2019-06-29 | 2022-03-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법 |
CN112569368A (zh) * | 2019-08-07 | 2021-03-30 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物及其应用 |
CA3108168A1 (en) * | 2020-02-05 | 2021-08-05 | Yue Zhang | Conjugates of cell-binding molecules with cytotoxic agents |
US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
CN112138170B (zh) * | 2020-09-28 | 2022-05-20 | 广东药科大学 | 一种预防顺铂药源性聋的缀合物及其制备方法和应用 |
CN112755173B (zh) * | 2020-12-31 | 2022-01-07 | 深圳市科达顺生物技术有限公司 | 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法 |
CN112961060B (zh) * | 2021-02-09 | 2022-03-25 | 武汉大学 | 同位素标记的n,n-二甲基乙二胺及其制备方法和短链脂肪酸的分析方法 |
CN115197297B (zh) | 2021-04-14 | 2023-08-01 | 启德医药科技(苏州)有限公司 | 连接子、缀合物及其应用 |
WO2022266354A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napoli |
WO2022078524A2 (en) * | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
WO2023209625A1 (en) * | 2022-04-28 | 2023-11-02 | Scirosbio (Fzc) | Compositions and methods for treatment of cancer |
WO2023244803A1 (en) * | 2022-06-17 | 2023-12-21 | The Regents Of The University Of California | Methods and compositions comprising tobacco mild green mosaic virus (tmgmv) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1521769B1 (de) * | 2002-07-09 | 2015-09-09 | Dömling, Alexander | Tubulysinkonjugate |
NZ599239A (en) * | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
JP6133431B2 (ja) * | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
KR20160142392A (ko) * | 2014-04-11 | 2016-12-12 | 메디뮨 엘엘씨 | 튜부리신 유도체 |
CN110279872A (zh) * | 2014-11-11 | 2019-09-27 | 杭州多禧生物科技有限公司 | 细胞毒素分子同细胞结合受体分子的共轭体 |
CN108026123B (zh) | 2015-06-15 | 2021-02-05 | 杭州多禧生物科技有限公司 | 用于偶联的亲水链接体 |
WO2015155753A2 (en) * | 2015-08-10 | 2015-10-15 | Suzhou M-Conj Biotech Co., Ltd | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
AU2016202632B2 (en) * | 2016-02-04 | 2021-09-09 | Hangzhou Dac Biotech Co, Ltd | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
BR112018071465A2 (pt) | 2016-04-20 | 2019-02-05 | Hangzhou Dac Biotech Co Ltd | derivados de toxinas de amanita e sua conjugação a uma molécula de ligação celular |
KR20220147720A (ko) * | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
KR20210122319A (ko) * | 2017-04-06 | 2021-10-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
-
2017
- 2017-12-31 MX MX2020006192A patent/MX2020006192A/es unknown
- 2017-12-31 CN CN201780094901.3A patent/CN111093707A/zh active Pending
- 2017-12-31 US US16/759,175 patent/US20200276261A1/en active Pending
- 2017-12-31 EP EP17936036.7A patent/EP3621652A4/en active Pending
- 2017-12-31 AU AU2017445144A patent/AU2017445144A1/en not_active Abandoned
- 2017-12-31 SG SG11202004801WA patent/SG11202004801WA/en unknown
- 2017-12-31 KR KR1020207019406A patent/KR102603344B1/ko active IP Right Grant
- 2017-12-31 WO PCT/CN2017/120454 patent/WO2019127607A1/en unknown
- 2017-12-31 NZ NZ764814A patent/NZ764814A/en unknown
- 2017-12-31 CA CA3085634A patent/CA3085634C/en active Active
- 2017-12-31 KR KR1020237017364A patent/KR102641565B1/ko active IP Right Grant
- 2017-12-31 EA EA202091217A patent/EA202091217A1/ru unknown
- 2017-12-31 BR BR112020010405-1A patent/BR112020010405A2/pt unknown
- 2017-12-31 JP JP2020535958A patent/JP7262817B2/ja active Active
-
2020
- 2020-05-18 PH PH12020550657A patent/PH12020550657A1/en unknown
- 2020-05-28 ZA ZA2020/03211A patent/ZA202003211B/en unknown
- 2020-06-10 IL IL275274A patent/IL275274A/en unknown
- 2020-06-15 CL CL2020001600A patent/CL2020001600A1/es unknown
-
2022
- 2022-07-15 AU AU2022205269A patent/AU2022205269A1/en active Pending
-
2023
- 2023-01-19 US US18/156,793 patent/US20230149502A1/en active Pending
- 2023-01-19 US US18/156,709 patent/US20230165930A1/en active Pending
- 2023-01-19 US US18/156,748 patent/US20230165931A1/en active Pending
- 2023-04-05 JP JP2023061065A patent/JP2023093531A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA202091217A1 (ru) | 2020-09-18 |
MX2020006192A (es) | 2020-08-20 |
CN111093707A (zh) | 2020-05-01 |
SG11202004801WA (en) | 2020-06-29 |
US20230165930A1 (en) | 2023-06-01 |
KR102641565B1 (ko) | 2024-02-27 |
US20230165931A1 (en) | 2023-06-01 |
JP2023093531A (ja) | 2023-07-04 |
IL275274A (en) | 2020-07-30 |
PH12020550657A1 (en) | 2021-04-19 |
KR102603344B1 (ko) | 2023-11-16 |
NZ764814A (en) | 2024-02-23 |
KR20200097295A (ko) | 2020-08-18 |
EP3621652A1 (en) | 2020-03-18 |
CA3085634C (en) | 2023-11-14 |
ZA202003211B (en) | 2024-04-24 |
WO2019127607A1 (en) | 2019-07-04 |
AU2022205269A1 (en) | 2022-08-11 |
KR20230075530A (ko) | 2023-05-31 |
JP7262817B2 (ja) | 2023-04-24 |
AU2017445144A1 (en) | 2020-06-18 |
CA3085634A1 (en) | 2019-07-04 |
US20230149502A1 (en) | 2023-05-18 |
JP2021507928A (ja) | 2021-02-25 |
EP3621652A4 (en) | 2021-01-13 |
BR112020010405A2 (pt) | 2020-11-24 |
US20200276261A1 (en) | 2020-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020001600A1 (es) | Un conjugado de un análogo de tubulisina con enlazadores ramificados. | |
PH12019502278A1 (en) | Conjugation of a cytotoxic drug with bis-linkage | |
EA202290091A1 (ru) | Конъюгат цитотоксического агента с клеточно-связывающей молекулой с разветвленными линкерами | |
EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
ZA202004099B (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
NZ741261A (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
NZ717003A (en) | Novel cytotoxic agents for conjugation of drugs to cell binding molecule | |
NZ754810A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
MX2019010804A (es) | Compuestos de benzazepina, conjugados y usos de los mismos. | |
PH12018501777A1 (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
NZ720743A (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
ECSP15025845A (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
UA111341C2 (uk) | Аматоксиновий кон'югат з покращеними лінкерами | |
UA111711C2 (uk) | Засіб імунотерапії деяких видів пухлин, у тому числі раку шлунково-кишкового тракту і раку шлунка | |
MX2019000277A (es) | Conjugados polimero-farmaco escindibles. | |
MA40030A (fr) | Conjugués peptide-médicament | |
WO2013181597A3 (en) | Thiol-ene click chemistry for drug conjugates | |
EA202091203A1 (ru) | Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b | |
AR108825A1 (es) | Conjugados de anticuerpo y fármaco dirigidos contra gcc | |
MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
MX2021003184A (es) | Hidrogeles de acido hialuronico degradables. | |
MX2020002802A (es) | Anticuerpos de cadena pesada que se unen a ectoenzimas. | |
UY35250A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos. | |
EA202092369A1 (ru) | Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака |